Analysis Of Patients With Advanced Solid Tumors Receiving Long-term ...
Connection issue
We're experiencing a technical problem connecting to this page. Please try again later.
Access deniedYou do not have access to www.researchgate.net.
The site owner may have set restrictions that prevent you from accessing the site.
- Ray ID: 9b252c158e168829
- Timestamp: 2025-12-23 04:38:55 UTC
- Your IP address: 103.110.85.167
- Requested URL: www.researchgate.net/publication/341637378_PROCLAIM-CX-072_Analysis_of_patients_with_advanced_solid_tumors_receiving_long-term_treatment_with_CX-072_a_PD-L1_probody_therapeutic_as_a_single_agent_or_in_combination_with_ipilimumab
- Error reference number: 1020
- Server ID: FL_411F260
- User-Agent: Mozilla/5.0 (Windows NT 6.3; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/63.0.3239.84 Safari/537.36
Ray ID: 9b252c158e168829
Client IP: 103.110.85.167
© ResearchGate GmbH. All rights reserved.
Từ khóa » Cx-072
-
CX-072 (pacmilimab), A Probody® PD-L1 Inhibitor, In Advanced Or ...
-
CX-072 (pacmilimab), A Probody PD-L1 Inhibitor, In Combination ...
-
CX-072 (pacmilimab), A Probody PD-L1 Inhibitor, In ... - PubMed
-
CX-072 (pacmilimab), A Probody ® PD-L1 Inhibitor, In Advanced Or ...
-
PROCLAIM-CX-072: Analysis Of Patients With Advanced Solid Tumors ...
-
PROCLAIM-CX-072: A Trial To Find Safe And Active Doses Of An ...
-
Study Of PD-L1 Probody Therapeutic CX-072 In Combination With ...
-
Preliminary Results Of PROCLAIM-CX-072: The First-in-human, Dose ...
-
The First-in-human, Dose-finding PROCLAIM-CX-072 Trial To Assess ...
-
Pipeline - CytomX
-
CX-072 In Patients With Advanced/recurrent Solid Tumours Or ...
-
Probody Therapeutic Design Of 89 Zr-CX-072 Promotes ...
-
PROCLAIM-CX-072: A Phase 1/2 Trial To Find The Best Dose And Test ...